BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 15370224)

  • 1. B-cell chronic lymphocytic leukemia with aberrant CD8 expression: genetic and immunophenotypic analysis of prognostic factors.
    Schroers R; Pukrop T; Dürig J; Haase D; Dührsen U; Trümper L; Griesinger F
    Leuk Lymphoma; 2004 Aug; 45(8):1677-81. PubMed ID: 15370224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prognostic factors for chronic lymphocytic leukemia with typical and atypical immunophenotype].
    Cao X; Xu W; Wu YJ; Qiao C; Liu Q; Fan L; Miao KR; Li JY
    Zhonghua Xue Ye Xue Za Zhi; 2009 Jul; 30(7):450-3. PubMed ID: 19954596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile.
    Wiestner A; Rosenwald A; Barry TS; Wright G; Davis RE; Henrickson SE; Zhao H; Ibbotson RE; Orchard JA; Davis Z; Stetler-Stevenson M; Raffeld M; Arthur DC; Marti GE; Wilson WH; Hamblin TJ; Oscier DG; Staudt LM
    Blood; 2003 Jun; 101(12):4944-51. PubMed ID: 12595313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia.
    Schroers R; Griesinger F; Trümper L; Haase D; Kulle B; Klein-Hitpass L; Sellmann L; Dührsen U; Dürig J
    Leukemia; 2005 May; 19(5):750-8. PubMed ID: 15759031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter study of ZAP-70 expression in patients with B-cell chronic lymphocytic leukemia using an optimized flow cytometry method.
    Gachard N; Salviat A; Boutet C; Arnoulet C; Durrieu F; Lenormand B; Leprêtre S; Olschwang S; Jardin F; Lafage-Pochitaloff M; Penther D; Sainty D; Reminieras L; Feuillard J; Béné MC;
    Haematologica; 2008 Feb; 93(2):215-23. PubMed ID: 18223290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia.
    Crespo M; Bosch F; Villamor N; Bellosillo B; Colomer D; Rozman M; Marcé S; López-Guillermo A; Campo E; Montserrat E
    N Engl J Med; 2003 May; 348(18):1764-75. PubMed ID: 12724482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ZAP-70, IgVh, and cytogenetics for assessing prognosis in chronic lymphocytic leukemia.
    Trojani A; Montillo M; Nichelatti M; Tedeschi A; Colombo C; Veronese S; Mura MA; Ricci F; Scarpati B; Colosimo A; Lodola M; Morra E
    Cancer Biomark; 2010; 6(1):1-9. PubMed ID: 20164537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia.
    Kröber A; Bloehdorn J; Hafner S; Bühler A; Seiler T; Kienle D; Winkler D; Bangerter M; Schlenk RF; Benner A; Lichter P; Döhner H; Stilgenbauer S
    J Clin Oncol; 2006 Feb; 24(6):969-75. PubMed ID: 16418492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of ZAP-70 protein correlates with disease stage in chronic lymphocytic leukemia and is associated with, but not generally restricted to, non-mutated Ig VH status.
    Kim SZ; Chow KU; Kukoc-Zivojnov N; Boehrer S; Brieger A; Steimle-Grauer SA; Harder L; Hoelzer D; Mitrou PS; Weidmann E
    Leuk Lymphoma; 2004 Oct; 45(10):2037-45. PubMed ID: 15370248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IgVH genes mutation and usage, ZAP-70 and CD38 expression provide new insights on B-cell prolymphocytic leukemia (B-PLL).
    Del Giudice I; Davis Z; Matutes E; Osuji N; Parry-Jones N; Morilla A; Brito-Babapulle V; Oscier D; Catovsky D
    Leukemia; 2006 Jul; 20(7):1231-7. PubMed ID: 16642047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone marrow infiltration pattern in B-cell chronic lymphocytic leukemia is related to immunoglobulin heavy-chain variable region mutation status and expression of 70-kd zeta-associated protein (ZAP-70).
    Schade U; Bock O; Vornhusen S; Jäger A; Büsche G; Lehmann U; Kreipe H
    Hum Pathol; 2006 Sep; 37(9):1153-61. PubMed ID: 16938520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic evaluation of CLLU1 expression levels in 50 Chinese patients with chronic lymphocytic leukemia.
    Chen L; Li J; Zheng W; Zhang Y; Wu Y; Li L; Qian S; Xu W
    Leuk Lymphoma; 2007 Sep; 48(9):1785-92. PubMed ID: 17786715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia.
    Kröber A; Seiler T; Benner A; Bullinger L; Brückle E; Lichter P; Döhner H; Stilgenbauer S
    Blood; 2002 Aug; 100(4):1410-6. PubMed ID: 12149225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency and prognostic impact of the aberrant CD8 expression in 5,523 patients with chronic lymphocytic leukemia.
    Kern W; Bacher U; Haferlach C; Alpermann T; Dicker F; Schnittger S; Haferlach T
    Cytometry B Clin Cytom; 2012 May; 82(3):145-50. PubMed ID: 22143984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-risk clonal evolution in chronic B-lymphocytic leukemia: single-center interphase fluorescence in situ hybridization study and review of the literature.
    Janssens A; Van Roy N; Poppe B; Noens L; Philippé J; Speleman F; Offner F
    Eur J Haematol; 2012 Jul; 89(1):72-80. PubMed ID: 22509718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telomere length, molecular cytogenetic findings, and immunophenotypic features in previously untreated patients with B-chronic lymphocytic leukemia.
    Brezinova J; Berkova A; Vcelikova S; Zemanova Z; Izakova S; Sarova I; Cechova H; Tajtlova J; Grosova L; Lizcova L; Malinova E; Zemanova M; Cmunt E; Karban J; Trneny M; Schwarz J; Michalova K
    Neoplasma; 2010; 57(3):215-21. PubMed ID: 20353271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping.
    Haferlach C; Dicker F; Schnittger S; Kern W; Haferlach T
    Leukemia; 2007 Dec; 21(12):2442-51. PubMed ID: 17805327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of flow cytometrically determined expression of ZAP-70 using the SBZAP antibody with IgVH mutation status and cytogenetics in 1,229 patients with chronic lymphocytic leukemia.
    Kern W; Dicker F; Schnittger S; Haferlach C; Haferlach T
    Cytometry B Clin Cytom; 2009 Nov; 76(6):385-93. PubMed ID: 19479984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of ZAP-70 expression by flow cytometry in chronic lymphocytic leukemia: A multicentric international harmonization process.
    Letestu R; Rawstron A; Ghia P; Villamor N; Boeckx N; Boettcher S; Buhl AM; Duerig J; Ibbotson R; Kroeber A; Langerak A; Le Garff-Tavernier M; Mockridge I; Morilla A; Padmore R; Rassenti L; Ritgen M; Shehata M; Smolewski P; Staib P; Ticchioni M; Walker C; Ajchenbaum-Cymbalista F
    Cytometry B Clin Cytom; 2006 Jul; 70(4):309-14. PubMed ID: 16906588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of flow cytometric methods for the measurement of ZAP-70 expression in a routine diagnostic laboratory.
    Gibbs G; Bromidge T; Howe D; Hopkins J; Johnson S
    Clin Lab Haematol; 2005 Aug; 27(4):258-66. PubMed ID: 16048494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.